LeukodermaNCT07662915
NCMT Technique and Jodhpur Technique and Excimer Laser in Treatment of Non Vitiligo Leucoderma
A study testing Melanocyte Keratinocyte Transplantation Procedure (MKTP), Jodhpur Technique and 308-nm Excimer Laser in people with Leukoderma, run by Al-Azhar University.
Trial summary
This study aims to compare the efficacy and safety of Melanocyte Keratinocyte Transplantation Procedure (MKTP) combined with 308-nm excimer laser versus Jodhpur technique combined with 308-nm excimer laser in the treatment of stable non-vitiligo leukoderma. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Leukoderma
- What is being tested?
- Melanocyte Keratinocyte Transplantation Procedure (MKTP), Jodhpur Technique and 308-nm Excimer Laser
- Type of treatment
- Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 22 participants
- Where
- No sites listed yet
- Study dates
- 1 Jul 2026to 1 Sep 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age 18 to 60 years.
- Clinically diagnosed stable non-vitiligo leukoderma.
- Stable lesion(s) for at least 6 months with no progression.
- Inadequate response to conventional medical therapy.
- Presence of two comparable lesions
- Willingness to participate and provide written informed consent.
Who cannot join
- Vitiligo or suspected active vitiligo.
- History of keloid or hypertrophic scar formation.
- Active infection at donor or recipient sites.
- Bleeding disorders or anticoagulant therapy that cannot be safely discontinued.
- Pregnancy or lactation.
- Immunosuppression or uncontrolled systemic disease.
- Inability to comply with follow-up visits.
- Unrealistic expectations regarding treatment outcome.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Efficacy and Safety of Melanocyte Keratinocyte Transplantation Procedure Plus 308-nm Excimer Laser in the Treatment of Non-Vitiligo Leukoderma
This study aims to compare the efficacy and safety of Melanocyte Keratinocyte Transplantation Procedure (MKTP) combined with 308-nm excimer laser versus Jodhpur technique combined with 308-nm excimer laser in the treatment of stable non-vitiligo leukoderma. Twenty-two patients with stable depigmented lesions will be enrolled. In each patient, two comparable lesions will be treated using different techniques. Clinical outcomes including percentage of repigmentation, color match, time to onset of repigmentation, complications, and histological changes will be assessed during follow-up to determine the optimal surgical treatment approach for non-vitiligo leukoderma.
- Conditions
- Leukoderma
- Being tested
- Melanocyte Keratinocyte Transplantation Procedure (MKTP), Jodhpur Technique, 308-nm Excimer Laser
- Medical subject headings
- Vitiligo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Melanocyte Keratinocyte Transplantation Procedure (MKTP)Procedure or surgery
Autologous melanocyte-keratinocyte cell suspension prepared using enzymatic separation and applied to a dermabraded recipient site.
Jodhpur TechniqueProcedure or surgery
Autologous non-cultured epidermal cell transfer technique using dermabraded donor skin particles applied directly to the recipient site without enzymatic processing
308-nm Excimer LaserDevice
Excimer laser therapy initiated approximately 14 days after surgery, administered twice weekly for 12-16 weeks with dose adjustment according to erythema response
| Study group | Role | What they receive |
|---|---|---|
| MKTP+ excimer laser | Experimental | Melanocyte Keratinocyte Transplantation Procedure followed by 308-nm excimer laser therapy Receives: Procedure: Melanocyte Keratinocyte Transplantation Procedure (MKTP); Device: 308-nm Excimer Laser |
| Jodhpur Technique + Excimer Laser | Experimental | Jodhpur technique followed by 308-nm excimer laser therapy Receives: Procedure: Jodhpur Technique; Device: 308-nm Excimer Laser |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Percentage Repigmentation of Target Lesions
Measured: 6 months
Secondary outcomes (2)
Time to Onset of Repigmentation
Measured: Up to 6 months
Color Match Assessment
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2026
- Study start1 Jul 2026 (estimated)
- Primary completion1 Jul 2026 (estimated)
- Study completion1 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LeukodermaStudies of the same condition, open and under way.
- More trials run by Al-Azhar UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 22 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Al-Azhar University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Mahmoud Mohamed Mahmoud, Al-Azhar University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07662915
- Sponsor's protocol ID
- RESEARCH/AZ.AST./DVA021/10/265
- Status last verified
- Jun 2026
- First submitted
- 17 Jun 2026
- Last updated
- 23 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Melanocyte Keratinocyte Transplantation Procedure Plus 308-nm Excimer Laser in the Treatment of Non-Vitiligo Leukoderma
- ClinicalTrials.gov ID
- NCT07662915
- Acronym / sponsor ID
- RESEARCH/AZ.AST./DVA021/10/265
- Conditions
- Leukoderma
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 22 participants (estimated)
- Lead sponsor
- Al-Azhar UniversityUniversity, hospital or other
- Study start
- 1 Jul 2026 (estimated)
- Primary completion
- 1 Jul 2026 (estimated)
- Study completion
- 1 Sep 2027 (estimated)
- First posted
- 23 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to compare the efficacy and safety of Melanocyte Keratinocyte Transplantation Procedure (MKTP) combined with 308-nm excimer laser versus Jodhpur technique combined with 308-nm excimer laser in the treatment of stable non-vitiligo leukoderma. Twenty-two patients with stable depigmented lesions will be enrolled. In each patient, two comparable lesions will be treated using different techniques. Clinical outcomes including percentage of repigmentation, color match, time to onset of repigmentation, complications, and histological changes will be assessed during follow-up to determine the optimal surgical treatment approach for non-vitiligo leukoderma.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MKTP+ excimer laser | Experimental | Procedure: Melanocyte Keratinocyte Transplantation Procedure (MKTP), Device: 308-nm Excimer LaserMelanocyte Keratinocyte Transplantation Procedure followed by 308-nm excimer laser therapy |
| Jodhpur Technique + Excimer Laser | Experimental | Procedure: Jodhpur Technique, Device: 308-nm Excimer LaserJodhpur technique followed by 308-nm excimer laser therapy |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Age 18 to 60 years.
- Clinically diagnosed stable non-vitiligo leukoderma.
- Stable lesion(s) for at least 6 months with no progression.
- Inadequate response to conventional medical therapy.
- Presence of two comparable lesions
Key exclusion criteria (8 listed)
- Vitiligo or suspected active vitiligo.
- History of keloid or hypertrophic scar formation.
- Active infection at donor or recipient sites.
- Bleeding disorders or anticoagulant therapy that cannot be safely discontinued.
- Pregnancy or lactation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Melanocyte Keratinocyte Transplantation Procedure (MKTP)Autologous melanocyte-keratinocyte cell suspension prepared using enzymatic separation and applied to a dermabraded recipient site. | Procedure or surgery | MKTP+ excimer laser |
| Jodhpur TechniqueAutologous non-cultured epidermal cell transfer technique using dermabraded donor skin particles applied directly to the recipient site without enzymatic processing | Procedure or surgery | Jodhpur Technique + Excimer Laser |
| 308-nm Excimer LaserExcimer laser therapy initiated approximately 14 days after surgery, administered twice weekly for 12-16 weeks with dose adjustment according to erythema response | Device | Jodhpur Technique + Excimer Laser, MKTP+ excimer laser |
Primary outcome
Mean Percentage Repigmentation of Target Lesions
Time frame: 6 months
2 secondary outcomes
Time to Onset of Repigmentation
Time frame: Up to 6 months
Color Match Assessment
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2026.
Related trials for Leukoderma
Recruiting
Effect of Kendall Versus McKenzie Exercises in Patients With Upper Crossed Syndrome
Upper Crossed Syndrome
RecruitingObservational study
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases
Inherited Ophthalmic Diseases, Hypopigmentation Disorder
Not yet recruitingPhase 2/3
Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo
Vitiligo
RecruitingObservational study
Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome
Hermansky-Pudlak Syndrome (HPS)
RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Vitiligo, Non-Segmental Vitiligo (NSV)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Melanocyte Keratinocyte Transplantation Procedure (MKTP), Jodhpur Technique and 308-nm Excimer Laser in people with Leukoderma, run by Al-Azhar University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mohamed Mahmoud (+201091865997, mas912m@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Percentage Repigmentation of Target Lesions (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2026.